Skip to content
OpenCapital
Get started

Integra LifeSciences IART EV / sales

EV / sales at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
2.7×-1.4×
Stryker logo
StrykerSYK
5.4×-1.3×
Axogen logo
AxogenAXGN
7×+2.5×
Globus Medical logo
Globus MedicalGMED
3.6×-0.2×
AbbVie logo
AbbVieABBV
7.5×+1.0×
Medtronic logo
MedtronicMDT
3.6×-0.4×

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Calculated from Integra LifeSciences’s reported figures.

enterprise value/total revenue=1.5×

Based on the most recent quarter.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's EV / sales?
Integra LifeSciences (IART) reported EV / sales of 1.5× in Q1 2026.
How has Integra LifeSciences's EV / sales changed year-over-year?
Integra LifeSciences's EV / sales decreased by 27.6% year-over-year, from 2.1× to 1.5×.
What is the long-term trend for Integra LifeSciences's EV / sales?
Over 5 years (2020 to 2025), Integra LifeSciences's EV / sales has grown at a -18.2% compound annual growth rate (CAGR), from 4.4× to 1.6×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.